# Otello Stampacchia

> Otello Stampacchia is a Series A investor at Omega Funds backing Biotechnology and Health Care. See 20 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Omega Funds](https://shizune.co/investors/profile/omega-funds)
- Location: Boston, United States
- Total investments: 20
- Last investment: May 2026
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/otello-stampacchia-82aa5a19/

Otello Stampacchia is a Series A investor at Omega Funds in Boston focused on Biotechnology and Health Care. Otello Stampacchia is based out of Geneva and is the Founder of Omega Funds. Otello previously worked at AlpInvest Partners as a Head, Life Sciences. Otello Stampacchia attended the Università di Pavia.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 50% |
| Health Care | 6 | 30% |
| Therapeutics | 6 | 30% |
| Medical | 5 | 25% |
| Life Science | 4 | 20% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 35% |
| Series B | 4 | 20% |
| Seed | 2 | 10% |
| Series C | 1 | 5% |
| Series D | 1 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 40% |
| France | 1 | 5% |
| Denmark | 1 | 5% |
| Germany | 1 | 5% |
| Switzerland | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M | Series B | May 04, 2026 |  |
| ARTBIO | ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $132M | Series B | Jul 29, 2025 |  |
| Antares Therapeutics | Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with significant unmet medical needs. Founded as a spin-out from Scorpion Therapeutics, it leverages proprietary drug discovery capabilities and arobust preclinical pipeline to advance multiple programs, primarily in precision oncology. | $177M | Series A | May 15, 2025 |  |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $200M | Series A | Jan 10, 2025 |  |
| Scorpion Therapeutics | Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $150M | Series C | Jul 16, 2024 |  |
| CatalYm | Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $150M | Series D | Jul 16, 2024 |  |
| ARTBIO | ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $90M | Series A | Dec 07, 2023 |  |
| ARTBIO | ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $23M | Seed | Jun 21, 2023 |  |
| Photys Therapeutics | Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, AmitChoudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler, Salk’s Tony Hunter, Berkeley’s Dan Nomura, MPM’s Wendy Young, and Dana Farber’s Eric Fischer. | $75M | Series A | Sep 08, 2022 |  |
| Aerium Therapeutics | Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants. |  | Series A | Mar 22, 2022 |  |

10 of 20 investments shown.

## Co-investors
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 6 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 6 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 5 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 4 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 4 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 4 deals together

## About Omega Funds

VC Fund · Boston, United States

Omega Funds is a venture capital firm that seeks to invest in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS sectors.

5 contacts available at Omega Funds.

| Name | Title | Profile |
| --- | --- | --- |
| Michael Powell | Executive Partner | https://shizune.co/investors/profile/michael-powell |
| Michael Powell | Executive Partner | https://shizune.co/investors/profile/mike-powell |
| Otello Stampacchia | Founder | https://shizune.co/investors/profile/otello-stampacchia |
| Vincent Ossipow | Partner | https://shizune.co/investors/profile/vincent-ossipow |
| Alexia Pearsall | Chief Financial Officer | https://shizune.co/investors/profile/alexia-pearsall-d875 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Otello Stampacchia invest in?

Otello Stampacchia invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Otello Stampacchia last invest?

The most recent investment recorded for Otello Stampacchia closed in May 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co